Stocks of Exact Sciences Corp. (NASDAQ:EXAS) traded higher last session on Wall Street, down -8.96% to $54.15.
EXAS stock price is now -14.58% away from the 50-day moving average and -21.14% away from the 200-day moving average. The market capitalization of the company currently stands at $9.96B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $91, The Benchmark Company recently Upgraded its rating from Hold to Buy for Exact Sciences Corp. (NASDAQ: EXAS). On December 14, 2023, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $90, while ‘Wolfe Research’ rates the stock as ‘Outperform’
In other news, Conroy Kevin T, President and CEO sold 1,155 shares of the company’s stock on May 01 ’24. The stock was sold for $69,473 at an average price of $60.15. Upon completion of the transaction, the President and CEO now directly owns 1,156,191 shares in the company, valued at $62.61 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01 ’24, Chief Commercial Officer Cunningham Everett sold 136 shares of the business’s stock. A total of $8,180 was realized by selling the stock at an average price of $60.15. This leaves the insider owning 47,042 shares of the company worth $2.55 million. A total of 1.04% of the company’s stock is owned by insiders.
During the past 12 months, Exact Sciences Corp. has had a low of $56.05 and a high of $100.77. As of last week, the company has a debt-to-equity ratio of 0.82, a current ratio of 1.64, and a quick ratio of 1.45.
According to the Diagnostics & Research Company, earnings per share came in at -0.45, beating analysts’ expectations of -0.51 by 0.06. This compares to -$0.42 EPS in the same period last year. The net profit margin was -9.48% and return on equity was -7.76% for EXAS. The company reported revenue of $637.52 million for the quarter, compared to $602.45 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.82 percent. For the current quarter, analysts expect EXAS to generate $700.15M in revenue.
